Simulations Plus (SLP) SEC Filings: History & Chart

Simulations Plus, Inc.(SLP)

Software - Application · Research Triangle Park, NC

$18.500.00 (0.00%)

Delayed quote: Oct 5, 2026, 4:00 PM EDT

About Simulations Plus, Inc.

Simulations Plus, Inc. (SLP) is a worldwide developer of sophisticated software and services aimed at enhancing drug discovery and development processes. The company employs artificial intelligence and machine learning technologies to create tools for modeling, simulation, and predicting molecular characteristics. Its operations are divided into four main business units: Simulations Plus, Cognigen, DILIsym, and Lixoft. Among its diverse software offerings are GastroPlus, which models the absorption and drug interactions of compounds in both human and animal subjects, as well as DDDPlus and MembranePlus for various simulations. The company also provides a range of products built on mechanistic and mathematical models, such as its quantitative systems pharmacology software like DILIsym, NAFLDsym, IPFsym, RENAsym, and MITOsym. Furthermore, Simulations Plus offers the ADMET Predictor, a chemistry-focused computer program that forecasts molecular properties from structural inputs, alongside MedChem Designer, MonolixSuite, and PKPlus for additional modeling and simulation needs. Beyond software, the company extends its expertise through various services, including contract research for population modeling and simulation, specialized training and consultation to advance pharmacometrics studies, and clinical-pharmacology consulting to aid in regulatory submissions. Simulations Plus serves a broad spectrum of clients globally, including pharmaceutical, biotechnology, agrochemical, cosmetic, and food companies, as well as academic institutions and regulatory bodies. The company was founded in 1996 and maintains its headquarters in Lancaster, California.

Research Triangle Park, NC

213 employees

www.simulations-plus.com

Technology / Software - Application

Sector: Technology
Industry: Software - Application
CEO: Shawn O'Connor

View full financials

Form	Filing Date	Accepted	Document
8-K	Aug 28, 2026	Aug 28, 2026	View filing
DEFA14A	Aug 21, 2026	Aug 21, 2026	View filing
8-K	Aug 13, 2026	Aug 13, 2026	View filing
SC 13G	Aug 6, 2026	Aug 6, 2026	View filing
4	Aug 4, 2026	Aug 4, 2026	View filing
DEFM14A	Jul 22, 2026	Jul 22, 2026	View filing
PRER14A	Jul 20, 2026	Jul 20, 2026	View filing
10-Q	Jul 9, 2026	Jul 9, 2026	View filing
8-K	Jul 9, 2026	Jul 9, 2026	View filing
PREM14A	Jul 9, 2026	Jul 9, 2026	View filing
4	Jul 8, 2026	Jul 8, 2026	View filing
4	Jul 6, 2026	Jul 6, 2026	View filing
4	Jun 17, 2026	Jun 17, 2026	View filing
8-K	Jun 17, 2026	Jun 17, 2026	View filing
4	Jun 16, 2026	Jun 16, 2026	View filing
8-K	Jun 16, 2026	Jun 16, 2026	View filing
4	Jun 4, 2026	Jun 4, 2026	View filing
4	Jun 2, 2026	Jun 2, 2026	View filing
4	May 13, 2026	May 13, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
4	May 5, 2026	May 5, 2026	View filing
4	May 1, 2026	May 1, 2026	View filing
4	May 1, 2026	May 1, 2026	View filing
4	May 1, 2026	May 1, 2026	View filing
4	May 1, 2026	May 1, 2026	View filing
4	Apr 16, 2026	Apr 16, 2026	View filing
10-Q	Apr 10, 2026	Apr 10, 2026	View filing
8-K	Apr 9, 2026	Apr 9, 2026	View filing
SC 13G/A	Mar 27, 2026	Mar 27, 2026	View filing
8-K	Feb 18, 2026	Feb 18, 2026	View filing

SEC Filings

Recent Filings